S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.42 (-0.28%)
AAPL   149.16 (+0.27%)
MSFT   307.43 (-0.26%)
FB   340.60 (+0.18%)
GOOGL   2,831.55 (-1.16%)
TSLA   860.60 (-0.42%)
AMZN   3,411.10 (-0.96%)
NVDA   221.03 (-0.84%)
BABA   177.15 (+0.08%)
NIO   39.56 (-1.17%)
CGC   14.25 (-0.63%)
GE   105.95 (+1.16%)
AMD   116.28 (-0.04%)
MU   68.06 (+0.73%)
T   25.89 (+1.17%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.16 (-0.60%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.83 (+0.07%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.42 (-0.28%)
AAPL   149.16 (+0.27%)
MSFT   307.43 (-0.26%)
FB   340.60 (+0.18%)
GOOGL   2,831.55 (-1.16%)
TSLA   860.60 (-0.42%)
AMZN   3,411.10 (-0.96%)
NVDA   221.03 (-0.84%)
BABA   177.15 (+0.08%)
NIO   39.56 (-1.17%)
CGC   14.25 (-0.63%)
GE   105.95 (+1.16%)
AMD   116.28 (-0.04%)
MU   68.06 (+0.73%)
T   25.89 (+1.17%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.16 (-0.60%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.83 (+0.07%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.42 (-0.28%)
AAPL   149.16 (+0.27%)
MSFT   307.43 (-0.26%)
FB   340.60 (+0.18%)
GOOGL   2,831.55 (-1.16%)
TSLA   860.60 (-0.42%)
AMZN   3,411.10 (-0.96%)
NVDA   221.03 (-0.84%)
BABA   177.15 (+0.08%)
NIO   39.56 (-1.17%)
CGC   14.25 (-0.63%)
GE   105.95 (+1.16%)
AMD   116.28 (-0.04%)
MU   68.06 (+0.73%)
T   25.89 (+1.17%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.16 (-0.60%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.83 (+0.07%)
S&P 500   4,536.19 (+0.37%)
DOW   35,609.34 (+0.43%)
QQQ   374.42 (-0.28%)
AAPL   149.16 (+0.27%)
MSFT   307.43 (-0.26%)
FB   340.60 (+0.18%)
GOOGL   2,831.55 (-1.16%)
TSLA   860.60 (-0.42%)
AMZN   3,411.10 (-0.96%)
NVDA   221.03 (-0.84%)
BABA   177.15 (+0.08%)
NIO   39.56 (-1.17%)
CGC   14.25 (-0.63%)
GE   105.95 (+1.16%)
AMD   116.28 (-0.04%)
MU   68.06 (+0.73%)
T   25.89 (+1.17%)
F   16.05 (+4.09%)
ACB   7.66 (+2.82%)
DIS   170.16 (-0.60%)
PFE   42.80 (+1.69%)
BA   216.23 (+0.12%)
AMC   40.83 (+0.07%)
NASDAQ:TCRR

TCR2 Therapeutics Price Target, Predictions & Analyst Ratings

$7.18
-0.70 (-8.88 %)
(As of 10/20/2021 03:59 PM ET)
Add
Compare
Today's Range
$7.10
$8.04
50-Day Range
$7.62
$18.35
52-Week Range
$7.62
$35.86
Volume98,563 shs
Average Volume506,988 shs
Market Capitalization$274.25 million
P/E RatioN/A
Dividend YieldN/A
Beta2.1

TCR2 Therapeutics (NASDAQ:TCRR) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Buy
Based on 10 Analyst Ratings

Analyst Price Target Consensus

$34.30

High PT$55.00
Average PT$34.30
Low PT$11.00
TypeCurrent
10/20/20 to 10/20/21
1 Month Ago
9/20/20 to 9/20/21
3 Months Ago
7/22/20 to 7/22/21
1 Year Ago
10/21/19 to 10/20/20
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$34.30$34.30$43.25$31.80
Price Target Upside377.72% Upside124.12% Upside73.89% Upside107.49% Upside
Get TCR2 Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

TCR2 Therapeutics (NASDAQ:TCRR) vs. Its Competitors

TypeTCR2 TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.90
2.72
2.56
Consensus RatingBuyBuyBuy
Price Target Upside142.88% Upside6.79% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
115
69.70%
Underperform Votes
50
30.30%
Avg. Outperform Votes
179
67.55%
Avg. Underperform Votes
86
32.45%
Avg. Outperform Votes
831
69.48%
Avg. Underperform Votes
365
30.52%

TCR2 Therapeutics (NASDAQ:TCRR) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/20/2021Truist
Asthika Goonewardene
Lower Price TargetBuy$40.00 ➝ $29.00+192.04%
9/20/2021Truist Securities
Lower Price TargetBuy$40.00 ➝ $29.00+190.29%
9/20/2021HC Wainwright
Reiterated RatingBuy$37.00 ➝ $25.00+150.25%
9/17/2021Wedbush
D. Nierengarten
DowngradeOutperform ➝ Neutral$45.00 ➝ $11.00+7.53%
8/6/2021SVB Leerink
Lower Price TargetOutperform$34.00 ➝ $31.00+125.95%
8/6/2021BMO Capital Markets
Lower Price TargetOutperform$53.00 ➝ $44.00+220.70%
8/5/2021Roth Capital
T. Butler
Reiterated RatingBuy
6/24/2021The Goldman Sachs Group
Initiated CoverageBuy$30.00+71.92%
5/13/2021Mizuho
Mara Goldstein
Initiated CoverageBuy$51.00+175.97%
3/11/2021Piper Sandler
Boost Price TargetOverweight$45.00 ➝ $55.00+94.55%
8/12/2020Truist Financial
Initiated CoverageBuy
3/11/2019Jefferies Financial Group
Initiated CoverageBuy ➝ Buy$31.00+98.21%
(Data available from 10/20/2016 forward. View 10+ years of historical ratings with our analyst ratings screener.)












TCR2 Therapeutics (NASDAQ:TCRR) Analyst Ratings Frequently Asked Questions

What is TCR2 Therapeutics's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for TCR2 Therapeutics stock is Buy based on the current 1 hold rating and 9 buy ratings for TCRR. The average twelve-month price target for TCR2 Therapeutics is $34.30 with a high price target of $55.00 and a low price target of $11.00. Learn more on TCRR's analyst rating history

Do Wall Street analysts like TCR2 Therapeutics more than its competitors?

Analysts like TCR2 Therapeutics stock more than the stock of other Medical companies. The consensus rating score for TCR2 Therapeutics is 2.90 while the average consensus rating score for medical companies is 2.72. Learn more on how TCRR compares to other companies

Do MarketBeat users like TCR2 Therapeutics more than its competitors?

MarketBeat users like TCR2 Therapeutics stock more than the stock of other Medical companies. 69.70% of MarketBeat users gave TCR2 Therapeutics an outperform vote while medical companies recieve an average of 67.55% outperform votes by MarketBeat users.

Is TCR2 Therapeutics being downgraded by Wall Street analysts?

Over the previous 90 days, TCR2 Therapeutics's stock had 1 downgrade by analysts.

Does TCR2 Therapeutics's stock price have much upside?

According to analysts, TCR2 Therapeutics's stock has a predicted upside of 124.12% based on their 12-month price targets.

What analysts cover TCR2 Therapeutics?

TCR2 Therapeutics has been rated by BMO Capital Markets, HC Wainwright, Roth Capital, SVB Leerink, Truist, Truist Securities, and Wedbush in the past 90 days.

This page was last updated on 10/20/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.